# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
In the coming months, partner GEICAM hopes to complete the remaining SIVs and the Company hopes to visit the remaining sites.
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its P...
The company announced that it has entered into a securities purchase agreement with its Chief Executive Officer, Snehal Patel, ...
HC Wainwright & Co. analyst Yi Chen reiterates Greenwich LifeSciences (NASDAQ:GLSI) with a Buy and maintains $36 price t...
Although U.S. stocks closed mostly lower on Friday, there were a few notable insider trades.
HC Wainwright & Co. analyst Yi Chen reiterates Greenwich LifeSciences (NASDAQ:GLSI) with a Buy and maintains $36 price t...
The Company's application to expand Flamingo-01 into Europe has been formally approved by Spain, France, Germany, Italy, an...